.png){kind=icon}
Return
Uric Acid
.png){kind=icon}
PRE
AI
DOI：10.1212/WNL.0000000000207825.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Uric acid (UA) is a strong endogenous antioxidant that neutralizes the toxicity of peroxynitrite and other reactive species on the neurovascular unit generated during and after acute brain ischemia. The realization that a rapid reduction of UA levels during an acute ischemic stroke was associated with a worse stroke outcome paved the way to investigate the value of exogenous UA supplementation to counteract the progression of redox-mediated ischemic brain damage. The long translational journey for UA supplementation recently reached a critical milestone when the results of the multicenter NIH stroke preclinical assessment network (SPAN) were reported. In a novel preclinical paradigm, 6 treatment candidates including UA supplementation were selected and tested in 6 independent laboratories following predefined criteria and strict methodological rigor. UA supplementation was the only intervention in SPAN that exceeded the prespecified efficacy boundary with male and female animals, young mice, young rats, aging mice, obese mice, and spontaneously hypertensive rats. This unprecedented achievement will allow UA to undergo clinical testing in a pivotal clinical trial through a NIH StrokeNet thrombectomy endovascular platform created to assess new treatment strategies in patients treated with mechanical thrombectomy. UA is a particularly appealing adjuvant intervention for mechanical thrombectomy because it targets the microcirculatory hypoperfusion and oxidative stress that limits the efficacy of this therapy. This descriptive review aims to summarize the translational development of UA supplementation, highlighting those aspects that likely contributed to its success. It includes having a well-defined target and mechanism of action, and an approach that simultaneously integrated rigorous preclinical assessment, with epidemiologic and preliminary human intervention studies. Validation of the clinical value of UA supplementation in a pivotal trial would confirm the translational value of the SPAN paradigm in preclinical research.
Keywords:
TISSUE-PLASMINOGEN ACTIVATOR
ISCHEMIC BRAIN-INJURY
ENDOVASCULAR THROMBECTOMY
THERAPY IMPROVES
NITRIC-OXIDE
STROKE
PEROXYNITRITE
NEUROPROTECTION
MECHANISM
GLUCOSE
Journal
IF:
8.5
Papers:
3.5W
Citations:
9.8W
Organization
View more organizations
Cited Papers
ShareSaveShareSaveShareSaveTrends in Use, Outcomes, and Disparities in Endovascular Thrombectomy in US Patients With Stroke Aged 80 Years and Older Compared With Younger Patients.png)
JAMA NETWORK OPEN
OAAI
JAMA NETWORK OPENIF9.7
OAAIShareSaveShareSavePrognostic significance of uric acid serum concentration in patients with acute ischemic strokeSTROKE
STROKEIF8.9
PREAI
ShareSave
View more